Clinical Trials Browser

Phase 2 × Recruiting × Borderline Resectable Pancreatic Adenocarcinoma × Clear all

NCT07240766 2026-02-13

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Phase 2 Recruiting

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma